Galatti Laura, Polimeni Giovanni, Salvo Francesco, Romani Marcello, Sessa Aurelio, Spina Edoardo
Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy.
Pharmacotherapy. 2006 Aug;26(8):1190-2. doi: 10.1592/phco.26.8.1190.
Memory loss and cognitive impairment have been reported in the literature in association with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), but we found no published case reports associated with rosuvastatin. To our knowledge, this is the first reported case of rosuvastatin-related short-term memory loss. A 53-year-old Caucasian man with hypercholesterolemia experienced memory loss after being treated with rosuvastatin 10 mg/day. He had no other concomitant conditions or drug therapies. After discontinuation of rosuvastatin, the neuropsychiatric adverse reaction resolved gradually, suggesting a probable drug association. During the following year, the patient remained free from neuropsychiatric disturbances. Clinicians should be aware of possible adverse cognitive reactions during statin therapy, including rosuvastatin.
文献中已报道记忆丧失和认知障碍与几种3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂(他汀类药物)有关,但我们未发现已发表的与瑞舒伐他汀相关的病例报告。据我们所知,这是首例报道的与瑞舒伐他汀相关的短期记忆丧失病例。一名53岁患有高胆固醇血症的白人男性在接受每日10毫克瑞舒伐他汀治疗后出现记忆丧失。他没有其他伴随疾病或药物治疗。停用瑞舒伐他汀后,神经精神不良反应逐渐缓解,提示可能与药物有关。在接下来的一年里,该患者未再出现神经精神障碍。临床医生应意识到他汀类药物治疗期间可能出现的不良认知反应,包括瑞舒伐他汀。